Differentiators When Choosing Novel Treatment Options for EDSPremiere Date: Friday, October 30, 2020
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
- ABP (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Monday, October 31, 2022
|Richard K. Bogan, MD, FCCP, FAASM
President, Bogan Sleep Consultants, LLC
Associate Clinical Professor
University of South Carolina School of Medicine
Associate Clinical Professor
Medical University of South Carolina
|Yves Dauvilliers, MD, PhD
Professor of Neurology and Physiology
University of Montpellier
Director, Sleep-Wake Disorders Centre
Department of Neurology
Gui de Chauliac Hospital
Reducing excessive daytime sleepiness (EDS) is an important treatment goal for patients with narcolepsy or obstructive sleep apnea (OSA). In order to achieve reduced EDS, cataplexy and sleep paralysis/hypnagogic hallucinations must be controlled to improve disturbed nighttime sleep, which then improves fatigue and brain fog and reduces psychosocial dysfunction, therefore improving quality of life (QoL). The latest efficacy and safety data should be reviewed, and considerations for treatment selection - especially in refractory patients, children, the elderly, or pregnant patients - must be taken into account.
This CMEOCast podcast focuses on developing personalized, effective strategies to reduce EDS in patients with OSA or narcolepsy, including an overview of data on incorporating the use of safer, lower sodium alternatives to mitigate EDS without imposing cardiovascular burden.
At the end of this CE activity, participants should be able to:
- Apply efficacy and safety data to treatment decisions for EDS in patients with OSA or narcolepsy to improve QoL and functioning.
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
Sleep specialists, pulmonologists, neurologists, psychiatrists, primary care physicians, pediatricians, PAs, nurse practitioners, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABP MOC Credit:
Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to .5 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
Royal College MOC:
Through an agreement between the Accreditation council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bogan reports that he is a consultant for Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc. He takes part in industry funded research with Avadel/Flamel Ireland LTD; Axsome Therapeutics, Inc.; Balance; Eisai Inc.; Fresca; Jazz Pharmaceuticals, Inc.; and Merck & Co., Inc. He is on the speakers bureau for Jazz Pharmaceuticals, Inc.; and Merck & Co., Inc. He is a shareholder, on the Board of Directors, the Chief Medical Officer, and an employee of SleepMed, Inc. He receives other financial or material support as a member of the Board of Directors for First Community Corporation, SC; and National Sleep Foundation.
Dr. Dauvilliers reports that he receives grants from Jazz Pharmaceuticals, Inc. He receives research support from Bioprojet; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and UCB S.A., Belgium. He is on the advisory committee for Bioprojet; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and UCB S.A., Belgium. He is a consultant for Bioprojet; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and UCB S.A., Belgium.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).